MoonLake Immunotherapeutics/$MLTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
Ticker
$MLTX
Sector
Primary listing
Employees
-
Headquarters
Zug, Switzerland
Website
MLTX Metrics
BasicAdvanced
$550M
-
-$2.79
1.27
-
Price and volume
Market cap
$550M
Beta
1.27
52-week high
$62.75
52-week low
$5.95
Average daily volume
6.3M
Financial strength
Current ratio
16.647
Quick ratio
15.661
Long term debt to equity
20.734
Total debt to equity
21.167
Interest coverage (TTM)
-97.70%
Profitability
EBITDA (TTM)
-199.04
Effective tax rate (TTM)
-0.21%
Management effectiveness
Return on assets (TTM)
-24.99%
Return on equity (TTM)
-40.34%
Valuation
Price to book
1.55
Price to tangible book (TTM)
1.55
Price to free cash flow (TTM)
-3.278
Free cash flow yield (TTM)
-30.51%
Free cash flow per share (TTM)
-2.642
Growth
Earnings per share change (TTM)
204.52%
3-year earnings per share growth (CAGR)
-19.47%
Bulls say / Bears say
MoonLake finished Q1 2025 with $480.1 million in cash and secured a $500 million non-dilutive debt facility, extending its cash runway into 2028 and decreasing dilution risk. (Nasdaq)
RBC Capital began coverage of MLTX with an Outperform rating and set an average 12-month price target of $80.24, indicating more than 100% potential upside. (Nasdaq)
Pharmaceutical heavyweight Merck held preliminary talks to acquire MoonLake for over $3 billion, sending shares up 19% on acquisition speculation. (Reuters)
In its VELA program for hidradenitis suppurativa, sonelokimab failed to achieve statistical significance in one Phase 3 trial and did not meet expectations in another, raising regulatory uncertainty and possibly requiring another pivotal study. (Investors.com)
Shares dropped nearly 90% in premarket trading, wiping out about $3.5 billion in market capitalization after disappointing trial results, underscoring high volatility and investor risk. (Barron’s)
Wolfe Research downgraded MLTX to Underperform and Citigroup lowered its rating to Neutral, highlighting widespread analyst pessimism following the Phase 3 setbacks. (MarketBeat)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
MLTX News
AllArticlesVideos
MoonLake Immunotherapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX
Business Wire6 days ago
MoonLake Investor News: Rosen Law Firm Encourages MoonLake Immunotherapeutics Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – MLTX
Business Wire6 days ago
MLTX Investors Have Opportunity to Join MoonLake Immunotherapeutics Fraud Investigation with the Schall Law Firm
Business Wire6 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MoonLake Immunotherapeutics stock?
MoonLake Immunotherapeutics (MLTX) has a market cap of $550M as of October 07, 2025.
What is the P/E ratio for MoonLake Immunotherapeutics stock?
The price to earnings (P/E) ratio for MoonLake Immunotherapeutics (MLTX) stock is 0 as of October 07, 2025.
Does MoonLake Immunotherapeutics stock pay dividends?
No, MoonLake Immunotherapeutics (MLTX) stock does not pay dividends to its shareholders as of October 07, 2025.
When is the next MoonLake Immunotherapeutics dividend payment date?
MoonLake Immunotherapeutics (MLTX) stock does not pay dividends to its shareholders.
What is the beta indicator for MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics (MLTX) has a beta rating of 1.27. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.